ethacridine has been researched along with Acute Myelogenous Leukemia in 2 studies
Ethacridine: A topically applied anti-infective agent.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rotin, LE | 2 |
| Gronda, M | 2 |
| MacLean, N | 2 |
| Hurren, R | 2 |
| Wang, X | 2 |
| Lin, FH | 2 |
| Wrana, J | 1 |
| Datti, A | 2 |
| Barber, DL | 1 |
| Minden, MD | 2 |
| Slassi, M | 1 |
| Schimmer, AD | 2 |
| Aman, A | 1 |
| Wrana, JL | 1 |
| Al-Awar, R | 1 |
2 other studies available for ethacridine and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
Ibrutinib synergizes with poly(ADP-ribose) glycohydrolase inhibitors to induce cell death in AML cells via a BTK-independent mechanism.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Animals; Apoptosis; Cell Line, Tumor; Drug Synergism; | 2016 |
Erlotinib synergizes with the poly(ADP-ribose) glycohydrolase inhibitor ethacridine in acute myeloid leukemia cells.
Topics: Cell Line, Tumor; Drug Synergism; Erlotinib Hydrochloride; Ethacridine; Glycoside Hydrolases; Humans | 2016 |